Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company Drug

CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review

Fineline Cube Apr 27, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...

Company Drug

Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment

Fineline Cube Apr 27, 2023

Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...

Company Deals

Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization

Fineline Cube Apr 27, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ,...

Drug Policy / Regulatory

NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings

Fineline Cube Apr 27, 2023

The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts...

Company Deals

Shanghai Fosun Pharmaceutical Reported to Halt Sale of Stake in Gland Pharma

Fineline Cube Apr 27, 2023

Indian media sources, including ET Now, have reported that Shanghai Fosun Pharmaceutical Group Co., Ltd...

Company Deals

LaNova Medicines and LegoChem Biosciences Partner to Develop Innovative ADC Product

Fineline Cube Apr 26, 2023

Shanghai-based cancer therapy developer LaNova Medicines Ltd has entered into a research partnership agreement with...

Company Deals

Sunshine Guojian Pharmaceutical and Shenyang 3SBio Secure Exclusive Licensing Agreement for Antitumor Programs

Fineline Cube Apr 26, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA

Fineline Cube Apr 26, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings...

Policy / Regulatory

Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages

Fineline Cube Apr 26, 2023

The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price...

Company Deals Digital

Ping An Healthcare and Technology Partners with Chugai Pharmaceutical to Establish Angina Pectoris Center

Fineline Cube Apr 26, 2023

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also recognized as PingAn Good Doctor,...

Company Drug

Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial

Fineline Cube Apr 26, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...

Company Deals

Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization

Fineline Cube Apr 26, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...

Company Drug

Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results

Fineline Cube Apr 26, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its...

Company Deals

Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech

Fineline Cube Apr 26, 2023

Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions...

Company Deals

Sable Therapeutics and Liuqiang Medical Ink Licensing Deal for Aesthetic Fat Reduction Patch

Fineline Cube Apr 26, 2023

US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical...

Company

Olympus Corp. to Invest $40.6 Million in New Endoscope Factory in Suzhou, China

Fineline Cube Apr 25, 2023

Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment...

Company Deals

Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software

Fineline Cube Apr 25, 2023

Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of...

Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Posts pagination

1 … 489 490 491 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.